![Noëlle Couget](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Noëlle Couget
Profile
Noëlle Couget worked as a Chief Financial Officer at Nokad SA and Serial Genetics SAS.
Former positions of Noëlle Couget
Companies | Position | End |
---|---|---|
Nokad SA
![]() Nokad SA Miscellaneous Commercial ServicesCommercial Services Nokad is a biotech start up created in January 2004 by three experienced scientists with scientific medical, pharmaceutical and business skills. The head office and the laboratory are located at Genopole d'Evry ( France ). Nokad developed a new technology that allows the inactivation of secreted proteins in vivo in 6 months, whatever the species required. Nokad was selected for pertinence and high potential for success by the Aventis-Institut de France Foundation in 2003 (Tremplins 2003). Nokad is supported by Genopole Entreprises. Recent Highlights Anticipated Highlights 8 secreted targets efficiently neutralized by the protein-function-KO technology, with Rat and mice protein-Knock-Out successfully obtained. Two new patents filled in 2006 and 2007, in thrombocytopenia treatment and in a Erythropoietin-mice and -rat model. Validation of a vaccination strategy for hypertriglyceridemia in 2009. Three contracts with pharmaceutical companies (Sanofi-Aventis, GSK, Servier). Multiple collaborative programs with pharmaceutical companies and academic groups. Corporate Mission The main objective of NOKAD is to follow the development and optimization of their technology platform for in vivo target validation. A secondary objective is the development of new therapeutic options based on vaccination against endogenous targets. Both side of their approach used the same platform set up since 2004. This innovative tool changes the way complex biologic questions can be solved in a short time. Furthermore, the proprietary protein-functional-Knock-Out technology allows testing the therapeutic options in all mammalians species before entering human clinical trials. This new way of thinking can potentially reduce the high failure rate of pharmaceutical drugs following their entry into clinical trials. | Director of Finance/CFO | 09/03/2014 |
Serial Genetics SAS
![]() Serial Genetics SAS Medical SpecialtiesHealth Technology Serial Genetics designs, develops and sells genetics analysis kits based on its proprietary technology, HairLoop and mutation discovery tools, based on the Endo-1 enzyme. Serial Genetics is an active partner of the 'Medicen Paris Region' competitiveness hub, dedicated to health and pharmaceutical research. Based in Evry, France, Serial Genetics is ideally situated in the hearth of the Genopole, the French largest cluster of biotech companies and genetic academic labs. | Director of Finance/CFO | 21/02/2013 |
Experiences
Positions held
Linked companies
Private companies | 2 |
---|---|
Nokad SA
![]() Nokad SA Miscellaneous Commercial ServicesCommercial Services Nokad is a biotech start up created in January 2004 by three experienced scientists with scientific medical, pharmaceutical and business skills. The head office and the laboratory are located at Genopole d'Evry ( France ). Nokad developed a new technology that allows the inactivation of secreted proteins in vivo in 6 months, whatever the species required. Nokad was selected for pertinence and high potential for success by the Aventis-Institut de France Foundation in 2003 (Tremplins 2003). Nokad is supported by Genopole Entreprises. Recent Highlights Anticipated Highlights 8 secreted targets efficiently neutralized by the protein-function-KO technology, with Rat and mice protein-Knock-Out successfully obtained. Two new patents filled in 2006 and 2007, in thrombocytopenia treatment and in a Erythropoietin-mice and -rat model. Validation of a vaccination strategy for hypertriglyceridemia in 2009. Three contracts with pharmaceutical companies (Sanofi-Aventis, GSK, Servier). Multiple collaborative programs with pharmaceutical companies and academic groups. Corporate Mission The main objective of NOKAD is to follow the development and optimization of their technology platform for in vivo target validation. A secondary objective is the development of new therapeutic options based on vaccination against endogenous targets. Both side of their approach used the same platform set up since 2004. This innovative tool changes the way complex biologic questions can be solved in a short time. Furthermore, the proprietary protein-functional-Knock-Out technology allows testing the therapeutic options in all mammalians species before entering human clinical trials. This new way of thinking can potentially reduce the high failure rate of pharmaceutical drugs following their entry into clinical trials. | Commercial Services |
Serial Genetics SAS
![]() Serial Genetics SAS Medical SpecialtiesHealth Technology Serial Genetics designs, develops and sells genetics analysis kits based on its proprietary technology, HairLoop and mutation discovery tools, based on the Endo-1 enzyme. Serial Genetics is an active partner of the 'Medicen Paris Region' competitiveness hub, dedicated to health and pharmaceutical research. Based in Evry, France, Serial Genetics is ideally situated in the hearth of the Genopole, the French largest cluster of biotech companies and genetic academic labs. | Health Technology |
- Stock Market
- Insiders
- Noëlle Couget